Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.9 - $8.02 $109,144 - $148,361
18,499 Added 34.63%
71,913 $468,000
Q1 2024

May 15, 2024

BUY
$7.5 - $12.07 $400,605 - $644,706
53,414 New
53,414 $443,000
Q4 2023

Feb 12, 2024

BUY
$6.01 - $11.48 $607,977 - $1.16 Million
101,161 New
101,161 $1.11 Million
Q3 2023

Nov 14, 2023

BUY
$8.24 - $12.97 $11,280 - $17,755
1,369 Added 1.56%
89,102 $749,000
Q2 2023

Aug 14, 2023

SELL
$9.99 - $18.27 $7.62 Million - $13.9 Million
-762,767 Reduced 89.68%
87,733 $1.1 Million
Q1 2023

May 12, 2023

SELL
$15.0 - $22.76 $3.01 Million - $4.57 Million
-200,925 Reduced 19.11%
850,500 $14 Million
Q4 2022

Feb 13, 2023

BUY
$14.16 - $24.02 $5.57 Million - $9.44 Million
393,040 Added 59.7%
1,051,425 $15.7 Million
Q3 2022

Nov 14, 2022

SELL
$18.07 - $31.37 $25.1 Million - $43.6 Million
-1,388,967 Reduced 67.84%
658,385 $14.7 Million
Q2 2022

Aug 15, 2022

BUY
$13.31 - $34.88 $357,213 - $936,109
26,838 Added 1.33%
2,047,352 $34.3 Million
Q1 2022

May 16, 2022

BUY
$20.26 - $32.36 $445,031 - $710,819
21,966 Added 1.1%
2,020,514 $60.5 Million
Q4 2021

Feb 11, 2022

BUY
$26.0 - $37.03 $15.4 Million - $21.9 Million
590,707 Added 41.96%
1,998,548 $61.4 Million
Q3 2021

Nov 15, 2021

BUY
$29.75 - $37.99 $4.15 Million - $5.31 Million
139,654 Added 11.01%
1,407,841 $44.4 Million
Q2 2021

Aug 16, 2021

BUY
$27.5 - $38.19 $11.6 Million - $16.2 Million
423,083 Added 50.06%
1,268,187 $46.4 Million
Q1 2021

May 17, 2021

BUY
$32.52 - $61.53 $22.8 Million - $43.2 Million
701,573 Added 488.8%
845,104 $29.2 Million
Q4 2020

Feb 12, 2021

SELL
$35.51 - $54.03 $2.74 Million - $4.17 Million
-77,257 Reduced 34.99%
143,531 $5.97 Million
Q3 2020

Nov 16, 2020

BUY
$32.81 - $45.1 $7.24 Million - $9.96 Million
220,788 New
220,788 $9.4 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $577M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.